Abstract. Aminopeptidase N (APN) is important in tumour processes. The present study detected the anti-tumour activity of the novel APN inhibitor DH-12a, which is an indoline-2,3-dione derivative. In the present study, Bestatin, a clinical APN inhibitor was used as a positive control. The expression of APN in the ES-2 and 3AO cell lines were assessed using flow cytometry and the drug inhibition constants of DH-12a (K i =13.15 µM) and Bestatin (K i =16.57 µM) were assessed using a double reciprocal method of competitive inhibition. The in vitro effects of DH-12a on cell proliferation were assessed using a 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay on human cell lines of ES-2 (IC 50 =43.8 µM), A549 (inhibition rate=41.5% at 160 µM DH-12a), HL60 (inhibition rate=47.83% at 160 µM DH-12a) and 3AO (IC 50 =70.2 µM). The inhibition rates were consistently higher than those of Bestatin. The effects of DH-12a on cell migration (inhibition rates in ES-2 cells and 3AO cells were 56.4 and 76.5%, respectively at 15 µM) and invasion (inhibition rates in ES-2 cells and 3AO cells were 75.6 and 66.5%, respectively at 15 µM) were assessed using transwell plates. The in vivo effects of DH-12a on tumour proliferation and lung tumour metastasis were determined using an H22 xenograft mice model, where DH-12a was administered in combination with genotoxic 5-fluorouracil. The anti-tumour activities of DH-12a in vivo were also greater than those of Bestatin. In conclusion, the in vitro effects of DH-12a on tumour proliferation, migration and invasion were consistent with the in vivo effects. In addition, DH-12a exhibited greater anti-tumour properties compared with Bestatin.
Introduction
Aminopeptidase N (APN; EC 3.4.11.2; CD13), also termed CD13, is a type 2 transmembrane zinc-dependent metallopeptidase of the superfamily of gluzincins (1, 2) . APN is expressed in numerous cells and tissues and is highly expressed in certain types of tumour, where it functions in tumour progression (3) . APN expression may be involved in the invasion and metastasis of cancer (4) (5) (6) (7) . Therefore, APN has been used as a new prognostic marker of cancer.
Bestatin is a dipeptide with a low molecular mass that functions as an APN inhibitor. It is also the only inhibitor of APN that has been used clinically as an adjuvant drug in the treatment of cancer, including leukaemia and ovarian carcinoma (8, 9) . However, the inhibition of APN by Bestatin is non-specific and exhibits lower efficacy and significant toxicity in the bone marrow and the gastric and intestinal mucosa (10, 11) . Therefore, it is necessary to identify new APN inhibitors with a low toxicity and high specificity.
DH-12a, a compound synthesised by Jin et al (12) , is more efficient at inhibiting the activity of APN than Bestatin. The structure of these two compounds is shown in Fig. 1 . In the present study, the possible functions of DH-12a in tumour progression were examined. As inhibition of APN/CD13 has been observed to suppress the progressive potential of ovarian carcinoma (OVCA) cells (13) , the OVCA cell lines ES-2 and 3AO were predominantly selected for in vitro investigation. Initially, APN in the ES-2 and 3AO cell lines were quantified. Using Bestatin as a positive control drug, the ability of DH-12a to inhibit the activity of APN and the inhibition constant of DH-12a to APN were determined. Subsequently, with Bestatin treatment as a positive control, the effects of DH-12a on cell proliferation were examined in the ES-2, A549, HL60 and 3AO cell lines using an MTT assay. The effects on cell invasion and cell migration were assessed in the ES-2 and 3AO cell lines using a Transwell plate. The anti-tumour activity of DH-12a was also determined in vivo, where DH-12a or Bestatin was combined with the genotoxic chemotherapeutic 5-fluorouracil (5-Fu). Flow cytometric analysis. Fluorescence-activated cell sorting (FACS) was performed to quantify the levels of APN expression on the surface of the ES-2 and 3AO cells. This was determined using methods described previously (3) . Cells were incubated with a APN/CD13 mouse-anti-human monoclonal antibody (BD Pharmingen) for 30 min at 4˚C in the dark. At the same time, the blank control group was administered with the same treatment with the exception of the monoclonal antibody. Subsequently, the cells were washed twice with phosphate-buffered saline (PBS) and then resuspended in PBS and analysed using a FACScan flow cytometer (FACSCalibur; Becton-Dickinson, San Jose, CA, USA) using Cell Quest software (BD FACSDiva 6.0; Becton-Dickinson). The levels of APN/CD13 were estimated as mean fluorescence intensity following subtracting those of the blank control group cells (14) .
Materials and methods

Cells
Enzyme activity assay. The activity of APN/CD13 on the surface of the ES-2 cells was determined using the methods described previously (12) . A cell suspension was prepared and then washed with PBS. Cells (5x10 5 ) were then suspended in PBS in each well of a 96-well plate containing various concentrations of Bestatin or DH-12a, with a final volume of 200 µl. The working concentrations of the two drugs were set as 2.5, 10, 40, 160 and 640 µM. Following incubation with 1.6 mM l-leucine-p-nitroanilide for 30 min at 37˚C, the enzyme activity was estimated by measuring the absorbance at 405 nm using a microplate reader (Model 680; Bio-Rad, Hercules, CA, USA). The APN activity inhibition rates of the compounds were calculated using the following formula: (ODcontrol -ODtested) / ODcontrol x 100%, where OD was the mean value of three replicate wells.
Assessment of the inhibition constant (K i ).
Determination of K i was constructed using the kinetics of aminopeptidase inhibition, as described previously (3). ES-2 cells (1x10 5 ) intensely expressed APN/CD13 and different concentrations of inhibitors (1, 2, 3, 4 and 5 µg/ml) were incubated with two concentrations of substrate (3.2 µM and 6.4 µM) at 37˚C, respectively. The reaction velocities were measured by monitoring the increasing absorbance at 405 nm every 1 min for 15 min. K i was calculated using the following equation: Cell proliferation assay. The cell proliferation assay was performed using methods described previously (15) . Cells (2,000 each) of the HL60, A549, ES-2 and 3AO cell lines were seeded into a 96-well plate and allowed to grow for 20 h. The cells were then treated with various concentrations of Bestatin (20, 40, 80, 160, 320 and 640 µM) or DH-12a (5, 10, 20, 40, 80 and 160 µM) for a further 48 h at a final volume of 200 µl. An MTT assay was performed by adding 20 µl MTT (5 mg/ ml) to each well followed by incubation for an additional 4 h. Subsequently, the culture was removed and 200 µl DMSO was added to dissolve the formazan crystals. The light absorbance of the solution at 490 nm (OD 490 ) was measured using an enzyme-linked immunosorbent assay reader (Model 680; Bio-Rad) and OD 630 was measured as a reference. The inhibitory rates of the APN inhibitors were calculated using the following formula: (ODcontrol -ODtested) / ODcontrol x 100%, where OD represents the mean value of three replicate wells. The IC 50 value was determined using Origin 7.5 software (OriginLab Corporation, Northampton, MA, USA).
In vitro migration assay. The inhibitory effect of DH-12a and Bestatin on the cell migration of the ES-2 or 3AO cell lines was evaluated in 24-well transwell plates (8 µm pore size; Corning Costar, Corning, NY, USA). Based on preliminary experiments, the cells were incubated in 6-well plates. Subsequently, 1x10 5 ES-2 or 3AO cells, which had been incubated with 15 µM DH-12a or 320 µM Bestatin for 48 h, were suspended in the upper chamber containing 200 µl serum-free RPMI-1640 with the same concentration of the drug. The lower chamber contained 600 µl RPMI-1640 supplemented with 10% NCS containing the same concentration of the drug. After 20 h incubation, the ES-2 or 3AO cells remaining on the upper surface of the filters were removed by wiping the surface with cotton swabs. The migrated cells on the lower surface of the filters were fixed with methanol (Laiyang Fine Chemical Factory, Yantai, China) for 10 min and then stained with 2 mg/ml crystal violet dye (Kermel, Tianjin, China) for 10 min. Images of the migrated cells were captured under a microscope (IX81; Olympus, Tokyo, Japan) and the results are presented as the mean number of migrated cells observed in five different fields.
In vitro invasion assay. An in vitro invasion assay was performed using invasion assays, as described previously (3). Matrigel was diluted 1:19 with serum-free RPMI-1640. The dilution (50 µl) was used to coat the upper transwell chamber for 1.5 h. The same cell migration assay was then conducted on the ES-2 and 3AO cells.
Assessment of DH-12a anti-tumour activity in vivo.
This assay was performed according to previously described methods (16) . In brief, a xenograft mouse model was established by subcutaneously inoculating 100 µl 7.6x10 6 H22 cells in the right armpit of 5-week-old female Kunming mice following adaptation for 1 week. For inoculation, the H22 cells were washed three times with sterile PBS and re-suspended in sterile PBS. Following growing for 5 days, any mice which were under or overweight were excluded and the remaining mice were randomly divided into four groups. For the drug treatment, the drugs (Bestatin, DH-12a and 5-Fu) dissolved in sterile PBS with 5% DMSO were administered by intraperitoneal injection for 5 days and withdrawn for 2 days. This procedure was performed in two courses for 14 days. Each group of mice was treated with one of the following: i) 5-Fu (30 mg/kg/day in the first course and 25 mg/kg/day in the second course for evident weight loss); ii) 5-Fu and Bestatin (20 mg/kg/day each); iii) 5-Fu and DH-12a (20 mg/kg/day each) and iv) PBS with 5% DMSO. These treatments were administered at a volume of 200 µl/20 g. The mice were then sacrificed and the liver, spleen and tumour of each mouse were weighed for statistical analysis.
Lung tumour metastasis assay. H22 cells (7.5x10 6 ) in 200 µl sterile PBS were injected into 4-6-week-old female Kunming mice by tail vein injection. After 24 h, the mice were randomly divided into four groups (17) . For the drug treatment, the drugs, dissolved in sterile PBS with 5% DMSO, were administered by intraperitoneal injection for 5 days and withdrawn for 2 days. This procedure was performed in two courses for 14 days. Each group of mice was treated with one of the following: i) 5-Fu (26.72 mg/kg); ii) 5-Fu (26.72 mg/kg) and Bestatin (63.34 mg/kg); iii) 5-Fu (26.72 mg/kg) and DH-12a (67.15 mg/kg) and iv) PBS with 5% DMSO. These treatments were administered at a volume of 200 µl/20 g. The mice were then sacrificed and the lung, liver and spleen of each mouse were weighed for statistical analysis. Lung tissues were then fixed with Bouin (Hede Biotechnology Co., Ltd., Beijing, China) and the nodes on each lung surface were counted. Single factor analysis of variance (ANOVA) with Origin 7.5 software (OriginLab Corporation, Northanpton, MA, USA) was used to calculate the overall difference.
Statistical analysis. The data are expressed as the mean ± standard deviation. Statistical analysis was performed by one-way ANOVA. P<0.05 was considered to indicate a statistically significant difference. Fig. 2 , FACS analysis revealed that the ES-2 cell line was positive for APN while the 3AO cell line was negative for APN. This result provided the basis for using ES-2 and 3AO cells to determine the biological activity of DH-12a as an APN inhibitor. Fig. 3 , DH-12a and Bestatin decreased the activity of APN in ES-2 cells in a dose-dependent manner. At concentrations between 2.5 and 640 µM, the mean inhibition rates of DH-12a on the activity of APN were significantly higher than that of Bestatin. The mean inhibition rates of DH-12a and Bestatin were 28.9 and 19.9% at 2.5 µM and 88.9 and 81.6% at 640 µM, respectively.
Results
Determination of APN expression. As shown in
Suppression of APN activity. As shown in
APN inhibition constants. Following construction of the standard curves of 1/ν vs.
[I] at different substrate concentrations, the K i of DH-12a and Bestatin was determined as -[I] at the point of intersection (Fig. 4) . For DH-12a, K i =13.15 µM; for Bestatin K i =16.57 µM. Fig. 5 , DH-12a and Bestatin elicited a dose-dependent effect on the four cell lines after 48 h exposure. In the ES-2 cells (Fig. 5A) , the maximum inhibition rates were 58.5% at 160 µM DH-12a (IC 50 =43.8 µM) and 34.7% at 640 µM Bestatin. In the 3AO cells (Fig. 5B) , the maximum inhibition rates were 53.9% at 160 µM DH-12a (IC 50 =70.2 µM) and 32.4% at 640 µM Bestatin. In addition, at the same concentration, Bestatin exhibited a higher inhibitory rate in the 3AO cells than in the ES-2 cells, while Bestatin is an APN inhibitor. As Fig. 5C and D show, in the HL60 and A549 cells, the inhibitory rates of DH-12a and Bestatin decreased more significantly than in the ES-2 and 3AO cells.
Inhibition of cell proliferation. As shown in
Decrease in cell migration. APN is also involved in tumour cell migration (18, 19) . By comparing the blank control groups, the present study found that the number of 3AO cells that migrated through the filter was markedly lower than that of the ES-2 cells. As shown in Fig. 6 , in ES-2 cells, the inhibitory rates on cell migration at 15 µM DH-12a and 320 µM Bestatin were 56.4 and 22.3%, respectively. In 3AO cells, the inhibitory rates at 15 µM DH-12a and 320 µM Bestatin were 76.5 and 22.2%, respectively.
Decrease in ES-2 and 3AO cell invasion.
The blank control groups demonstrated a significantly higher number of ES-2 cells that had migrated through the matrix than in the 3AO cells (data not shown). In the ES-2 cells, the inhibitory rates of DH-12a and Bestatin were 75.6 and 43.9%, respectively (Fig. 7) , whereas in the 3AO cells, the inhibitory rates of DH-12a and Bestatin were 66.5 and 51.4%, respectively.
Tumour inhibition in vivo.
Among the four groups, only the group treated with Bestatin combined with 5-Fu successfully yielded two non-tumourigenic mice. The other groups comprised tumourigenic mice. As shown in Fig. 8 , the mean tumour weights of the groups treated with DH-12a combined with 5-Fu, Bestatin combined with 5-Fu and 5-Fu alone were 0.59, 0.90 and 0.85 g, respectively. The mean tumour weight in the blank group was 2.76 g. In addition, no weight loss or increased quality of the liver or spleen was observed in the three drug-treated groups at the end of the experiment.
Depression of lung tumour metastasis. As shown in Fig. 9 , the mean number of nodules in the groups treated with DH-12a Bestatin combined with 5-Fu and the blank group had a standard deviation >20. In addition, no weight loss or increased quality in liver or spleen was observed in the three drug-treated groups at the end of the experiment.
Discussion
Previous studies have revealed that APN is involved in enhanced cell viability, cell migration and tumour inva- A B sion (20) (21) (22) (23) (24) . In the present study, the results from FACS analysis demonstrated that ES-2 cells markedly expressed APN. This result was consistent with the result of a previous study (3) . By contrast, the 3AO cells were negative for APN. These results were favorable for determining the anti-tumour activity of DH-12a as an APN inhibitor. The result of the enzyme activity assay demonstrated that inhibition of APN activity induced by DH-12a was significantly higher than that by Bestatin at the same concentration. The result of the inhibition constant assay demonstrated that DH-12a yielded a smaller APN inhibition constant than Bestatin, indicating that DH-12a had a stronger APN binding capacity than Bestatin. Therefore, DH-12a was a stronger inhibitor of APN than Bestatin. Considering that expression of APN in OVCA cells stimulates cell proliferation and tumour invasion (21) , the present study determined the effects of DH-12a on cell viability, cell migration and invasion of the ES-2 and 3AO cell lines. In these experiments, Bestatin was used as the positive control treatment.
In the MTT assay, HL60 and A549 cell lines, which have been demonstrated to have a high expression of APN, were involved. The results demonstrated that the proliferation of ES-2 and 3AO cells were markedly inhibited by DH-12a and the inhibition by DH-12a was significantly higher than that of Bestatin. Notably, no difference in the inhibition of cell viability by the two drugs was observed between the ES-2 and 3AO cells. In the HL60 and A549 cell lines, the inhibitory rates declined compared with those of the ES-2 or 3AO cell lines, which indicated that DH-12a and Bestatin, as APN inhibiting drugs, had specificity for OVCA cell lines. This was consistent with the application of Bestatin in clinical tumour treatment. In all cell lines, DH-12a persistently exhibited a stronger anti-tumour activity than Bestatin.
The present study also investigated the effect of DH-12a on cell migration and invasion in the ES-2 and 3AO cell lines using a transwell plate assay. In these two assays, the migratory ability and invasive ability of the 3AO cells were significantly weaker than those of the ES-2 cells. This weak ability may be attributed to the low expression of APN in 3AO cells. These findings are consistent with previous studies, in which APN was reported to function in tumour angiogenesis and tumour invasion (12, 25) . In these two assays, DH-12a exhibited persistently and significantly higher inhibitory rates than Bestatin at the same concentration, suggesting that DH-12a was able to inhibit cell migration or invasion in the OVCA cell lines to a greater extent than Bestatin. However, in 3AO and ES-2 cell lines, neither DH-12a nor Bestatin demonstrated an increased inhibitory rate in the ES-2 cell line, suggesting that APN inhibitors have other targets in the OVCA cell lines. In addition, DH-12a is possibly a non-specific APN inhibitor exhibiting a more marked anti-tumour activity than Bestatin.
All the in vitro assays indicated that DH-12a exerted a superior anti-tumour ability compared with Bestatin, and that inhibition of the in vitro cell migration and invasion of the 3AO cell line, which was APN negative, suggested that other targets in the OVCA cell lines were important in the progress of the 3AO and ES-2 cell lines.
The in vivo assay revealed that 5-Fu, Bestatin combined with 5-Fu and DH-12a combined with 5-Fu markedly inhibited tumour growth and lung tumour metastasis without exhibiting evident biological toxicity. Tumour inhibition was most marked in the group treated with DH-12a combined with 5-Fu, suggesting that DH-12a exhibited more effective anti-tumour activity than Bestatin. DH-12a may reduce the toxicity and enhance the efficacy of treatment compared with genotoxic chemotherapeutic 5-Fu alone.
In conclusion, DH-12a exhibited a stronger ability in inhibiting cancer cell proliferation than Bestatin in the four cell lines. The ability of DH-12a to inhibit in vitro cell migration and cell invasion was also significantly higher than Bestatin in the 3AO and ES-2 cell lines. In vivo, DH-12a exhibited good biocompatibility in mice and its anti-tumour ability was higher than that of Bestatin. In conclusion, as an initial investigation of 
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potential drugs for inhibition of APN, the present study provided encouraging results and thus further investigation of DH-12a for clinical application is required.
